The global Biological Drugs market was valued at US$ 291940 million in 2022 and is projected to reach US$ 495400 million by 2029, at a CAGR of 7.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Biological Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Biological Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Biological Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The international biological drugs market is envisaged to grow at a handsome rate in the next few years. However, it could face challenges in the form of various product parameters, strict regulatory pathways and manufacturing processes, and longer product approvals, although biological drugs have historically shown better approval rates than conventional ones. Additionally, small players could find it difficult to enter the market because of the requirement of high capital expenditure.
This report aims to provide a comprehensive presentation of the global market for Biological Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Drugs. This report contains market size and forecasts of Biological Drugs in global, including the following market information:
- Global Biological Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global Biological Drugs Market Sales, 2018-2023, 2024-2030, (Units)
- Global top five Biological Drugs companies in 2022 (%)
The world biological drugs market is predicted to gain momentum with rising prevalence of chronic diseases such as cancer and diabetes across the globe. Demand for biological drugs could swell with the expansion of geriatric population at the global level. Currently growing inclination toward adoption of personalized medicines and strong research and development efforts taken to introduce new and powerful biological drugs are foretold to set the tone for a significant rise in demand.
We surveyed the Biological Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Biological Drugs Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Biological Drugs Market Segment Percentages, by Type, 2022 (%)
- Therapeutic Protein
- Monoclonal Antibody
- Vaccine
- Others
Global Biological Drugs Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Biological Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospitals
- Ambulatory Surgical Centers
- Others
Global Biological Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (Units)
Global Biological Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Biological Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
- Key companies Biological Drugs revenues share in global market, 2022 (%)
- Key companies Biological Drugs sales in global market, 2018-2023 (Estimated), (Units)
- Key companies Biological Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Bristol-Myers Squibb
- Eli Lilly
- Takeda
- Pfizer
- Amgen
- F. Hoffmann-La Roche
- Johnson & Johnson
- Merck
- Abbott Laboratories
- Baxter
- Novartis
- Biogen
- GlaxoSmithKline
Outline of Major Chapters:
Chapter 1: Introduces the definition of Biological Drugs, market overview.
Chapter 2: Global Biological Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Biological Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Biological Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Biological Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
